Revance Therapeutics Inc (RVNC)

[DewDiligence]

RVNC fully-diluted shares @7/28/21=89.8M—an increase of 0.2M since 3/31/21 (#msg-163911810).

As explained on page 40 of the 2Q21 10-Q (https://www.sec.gov/ix?doc=/Archives/edgar/data/1479290/000147929021000150/rvnc-20210630.htm ), the above figure consists of: 71.8 basic shares; 4.9M options; 4.1M shares of (already issued) unvested restricted stock awards; and 8.9M shares deriving from the convertible debt issued in Feb 2020 (ignoring hedging transactions associated with the convertible debt).

(Excluding the shares derived from the convertible debt, fully-diluted shares at 7/28/21 were 80.9M.)

Note: RVNC did not sell any shares under the ATM facility during 2Q21 or during 3Q21 through 7/28/21 (the date of the accounting on p.40 of the 2Q21 10-Q).